Navigation Links
Gallo Center scientists identify key brain circuits that control compulsive drinking in rats
Date:7/22/2013

A research team led by scientists from the Ernest Gallo Clinic and Research Center at the University of California, San Francisco has identified circuitry in the brain that drives compulsive drinking in rats, and likely plays a similar role in humans.

The scientists found they could reduce compulsive drinking in rats by inhibiting key neural pathways that run between the prefrontal cortex, which is involved with higher functions such as critical thinking and risk assessment, and the nucleus accumbens, a critical area for reward and motivation.

The authors noted that there are already several FDA-approved medications that target activity in these pathways, thus potentially opening an accelerated track to new treatments for compulsive drinking.

The study describing their finding was published online on June 30 in Nature Neuroscience.

The study was conducted on rats that regularly drank 20 percent alcohol. The rats drank both unmixed alcohol and alcohol mixed with extremely bitter quinine, said senior investigator F. Woodward Hopf, PhD, an assistant adjunct professor of neurology at UCSF.

Hopf explained that this alcohol-quinine solution, which he described as like a vodka tonic without the sugar, is often used as a rodent model of compulsive drinking, or drinking in the face of negative consequences. In rats, he said, the negative consequence is the bitter taste, while in humans who drink compulsively, the negative consequences are profound: people continue to drink despite the potential loss of jobs, marriages, freedom, even their lives.

In the United States, alcoholism is estimated to cost $224 billion per year almost $2 per drink mostly from lost productivity and crime, and leads to 100,000 preventable deat
'/>"/>

Contact: Jeffrey Norris
jeff.norris@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. BGI and Association of Czech genetic centers announce opening of a joint prenatal test facility
2. UChicago Celiac Disease Center to host international symposium
3. MIT and Wilson Center receive NSF grant to develop synthetic biology research agenda
4. Emory, Georgia Tech receive first human exposome center grant in US
5. U-M Water Center awards $570K in Great Lakes restoration grants
6. NSF approves planning grant for Center for Advanced Research in Drying
7. Center for Clinical and Translational Science awards new pilot grants
8. University of Maryland Medical Center launches genetic-testing program for cardiac patients
9. Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
10. NYU Langone Medical Center researcher named Howard Hughes Investigator
11. Scientists discover how brains auditory center transmits information for decisions, actions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Ind. - One of the world,s most destructive wheat ... its host, according to a study that mapped the ... and U.S. Department of Agriculture research plant pathologist, was ... genome of the fungus Mycosphaerella graminicola, which causes septoria ...
... conference, titled "Supporting the worldwide implementation of the ... the Global Partnership for Plant Conservation (GPPC) in ... Biological Diversity (CBD) and Botanic Gardens Conservation International ... wide range of participants to share their experiences ...
... the road toward a coherent energy policy that focuses ... issues and realities. These include: the finite supply and ... to implement a widespread switch to renewable energy sources, ... particular types of power generation. They also need ...
Cached Biology News:Genome offers clue to functions of destructive wheat fungus 2Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 2Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 3The energy debate: Coal vs. nuclear 2The energy debate: Coal vs. nuclear 3
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
(Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
... proteins in polyacrylamide gel after SDS ... ng of protein) with *CoomassieR-G250. All ... can be performed in 1.5 hr. ... proteins can be seen before destaining. ...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
Biology Products: